Prediction of non-resectability in tubo-ovarian cancer patients using Peritoneal Cancer Index - A prospective multicentric study using imaging (ISAAC study).

Computed tomography Laparoscopy Laparotomy Magnetic resonance Ovarian cancer Staging Ultrasonography

Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
10 Oct 2024
Historique:
received: 10 07 2024
revised: 30 09 2024
accepted: 01 10 2024
medline: 12 10 2024
pubmed: 12 10 2024
entrez: 11 10 2024
Statut: aheadofprint

Résumé

The aim was to evaluate the performance of the Peritoneal Cancer Index (PCI) using imaging (ultrasound, contrast-enhanced computed tomography (CT), and whole-body diffusion-weighted magnetic resonance imaging (WB-DWI/MRI) in assessing peritoneal carcinomatosis and predicting non-resectability in tubo-ovarian carcinoma patients. This was a prospective multicenter observational study. We considered all patients with suspected primary ovarian/tubal/peritoneal cancer who underwent preoperative ultrasound, CT, and WB-DWI/MRI (if available). The optimal cut off value for assessing the performance of the methods in predicting non-resectability was identified at the point at which the sensitivity and specificity were most similar. The reference standard to predict non-resectability was surgical outcome in terms of residual disease >1 cm or surgery not feasible. Agreement between imaging methods and surgical exploration in assessing sites included in the PCI score was evaluated using the Intraclass Correlation Coefficient (ICC). 242 patients were included from January 2020 until November 2022. The optimal PCI cut-off for predicting non-resectability for surgical exploration was >12, which achieved the best AUC of 0.87, followed by ultrasound with a cut-off of >10 and AUC of 0.81, WB-DWI/MRI with a cut-off of >12 and AUC of 0.81, and CT with a cut-off of >11 and AUC of 0.74. Using ICC, ultrasound had very high agreement (0.94) with surgical PCI, while CT and WB-DWI/MRI had high agreement (0.86 and 0.87, respectively). Ultrasound performed by an expert operator had the best agreement with surgical findings compared to WB-DWI/MRI and CT in assessing radiological PCI. In predicting non-resectability, ultrasound was non-inferior to CT, while its non-inferiority to WB-DWI/MRI was not demonstrated.

Sections du résumé

BACKGROUND BACKGROUND
The aim was to evaluate the performance of the Peritoneal Cancer Index (PCI) using imaging (ultrasound, contrast-enhanced computed tomography (CT), and whole-body diffusion-weighted magnetic resonance imaging (WB-DWI/MRI) in assessing peritoneal carcinomatosis and predicting non-resectability in tubo-ovarian carcinoma patients.
METHODS METHODS
This was a prospective multicenter observational study. We considered all patients with suspected primary ovarian/tubal/peritoneal cancer who underwent preoperative ultrasound, CT, and WB-DWI/MRI (if available). The optimal cut off value for assessing the performance of the methods in predicting non-resectability was identified at the point at which the sensitivity and specificity were most similar. The reference standard to predict non-resectability was surgical outcome in terms of residual disease >1 cm or surgery not feasible. Agreement between imaging methods and surgical exploration in assessing sites included in the PCI score was evaluated using the Intraclass Correlation Coefficient (ICC).
RESULTS RESULTS
242 patients were included from January 2020 until November 2022. The optimal PCI cut-off for predicting non-resectability for surgical exploration was >12, which achieved the best AUC of 0.87, followed by ultrasound with a cut-off of >10 and AUC of 0.81, WB-DWI/MRI with a cut-off of >12 and AUC of 0.81, and CT with a cut-off of >11 and AUC of 0.74. Using ICC, ultrasound had very high agreement (0.94) with surgical PCI, while CT and WB-DWI/MRI had high agreement (0.86 and 0.87, respectively).
CONCLUSION CONCLUSIONS
Ultrasound performed by an expert operator had the best agreement with surgical findings compared to WB-DWI/MRI and CT in assessing radiological PCI. In predicting non-resectability, ultrasound was non-inferior to CT, while its non-inferiority to WB-DWI/MRI was not demonstrated.

Identifiants

pubmed: 39393218
pii: S0090-8258(24)01153-3
doi: 10.1016/j.ygyno.2024.10.003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

132-142

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Auteurs

Patrícia Pinto (P)

Department of Gynecology, Portuguese Institute of Oncology of Lisbon Francisco Gentil, Lisbon, Portugal; First Faculty of Medicine, Charles University and General University Hospital in Prague.

Francesca Moro (F)

Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Rome, Italy.

Juan Luis Alcázar (JL)

QuironSalud Hospital, Málaga, Spain; Department of Obstetrics and Gynecology, Clínica Universidad de Navarra, Pamplona, Spain.

Sarah Alessi (S)

Division of Radiology, IEO European Institute of Oncology IRCCS, Milan, Italy.

Giacomo Avesani (G)

Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy.

Klára Benesova (K)

Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Andrea Burgetova (A)

Department of Radiology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Giuseppina Calareso (G)

Department of Radiology, IRCCS Fondazione Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Valentina Chiappa (V)

Department of Gynecologic Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

David Cibula (D)

Gynecologic Oncology Centre, Department of Gynecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.

Anna Fagotti (A)

Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Rome, Italy.

Dorella Franchi (D)

Preventive Gynecology Unit, Division of Gynecology, European Institute of Oncology IRCCS, Milan, Italy.

Filip Frühauf (F)

Gynecologic Oncology Centre, Department of Gynecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.

Jiri Jarkovsky (J)

Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Roman Kocian (R)

Gynecologic Oncology Centre, Department of Gynecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.

Lukas Lambert (L)

Department of Radiology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Martin Masek (M)

Department of Radiology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Camilla Panico (C)

Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy.

Paola Pricolo (P)

Division of Radiology, IEO European Institute of Oncology IRCCS, Milan, Italy.

Giovanni Scambia (G)

Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Rome, Italy.

Jiri Slama (J)

Gynecologic Oncology Centre, Department of Gynecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.

Antonia Carla Testa (AC)

Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Rome, Italy.

Ailyn Mariela Vidal Urbinati (AMV)

Preventive Gynecology Unit, Division of Gynecology, European Institute of Oncology IRCCS, Milan, Italy.

Julio Vara Garcia (JV)

Department of Obstetrics and Gynecology, Clínica Universidad de Navarra, Pamplona, Spain.

Raffaella Vigorito (R)

Department of Radiology, IRCCS Fondazione Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Daniela Fischerová (D)

Gynecologic Oncology Centre, Department of Gynecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. Electronic address: daniela.fischerova@vfn.cz.

Classifications MeSH